4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments

Abstract

The present invention relates to 4-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

1 . A 4-substituted pyrazoline compound of general formula I,  
       
         
           
           
               
               
           
         
       
       wherein 
 X is O or S;  
 R 1  and R 2 , independently of one another, in each case represent an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system; 
 or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 
 R 3  an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical which together with a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical forms a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing spirocyclic residue via a common ring atom;  
 a —O—R 6  moiety; a —NR 7 R 8  moiety or a —NR 9 —O—R 10  moiety;  
 
 R 4  represents F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group:  
 an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an optionally at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 a —O—R 11  moiety; a —S—R 12  moiety; a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
 
 R 5  represents H; F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 a —O—R 11  moiety; a —S—R 12  moiety; a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
 
 or R 4  and R 5  together with the bridging carbon atom form a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical;  
 R 6  represents a hydrogen atom; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety or a —C(═O)—R 19  moiety;  
 
 R 7  and R 8 , independently of one another, in each case represent a hydrogen atom; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical which together with a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical forms a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing spirocyclic residue via a common ring atom;  
 an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety; a —C(═O)—R 19  moiety; a —S(═O) 2 —R 20  moiety; or a —NR 21 R 22  moiety;  
 
 R 9  represents hydrogen or a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 R 10 , R 11 , R 12 , R 13 , R 14 , R 15  and R20, independently of one another, in each case represent a saturated or unsaturated, unsubstituted or at least 
 mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatorn as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted alkylene group;  
 or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 
 R 16 , R 17 , R 18  and R 19 , independently of one another, in each case represent a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical, 
 or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or m ay be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 and  
 
 R 21  and R 22 , independently of one another, in each case represent a hydrogen atom; 
 a saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical which together with a saturated or unsaturated, unsubstituted or at least monosubstituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical forms a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing spirocyclic residue via a common ring atom;  
 or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted alkylene group, alkenylene group or alkinylene group;  
 whereby the following compounds are excluded  
 
 [A] ethyl 4,5-dimorpholino-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [B] methyl 1-phenyl-4,5-di(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [C] 1-(4-chlorophenyl)-4-(hydroxymethyl)-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid,  
 [D] ethyl 5-morpholino-1,4-diphenyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [E] ethyl 4-(4-chlorophenyl)-1-(4-fluorophenyl)-5-morpholino-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [F] ethyl 1-(4-fluorophenyl)-5-morpholino-4-p-tolyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [G] methyl 4-(hydroxymethyl)-1-(2-(methoxycarbonyl)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [H] benzofuran-2-yl(5-(4-hydroxyphenyl)-4-nitro-1-(3-phenyl-1H-pyrazol-5-yl)-4,5-dihydro-1H-pyrazol-3-yl)methanone,  
 [I] (5-(benzo[d][1,3]dioxol-5-yl)-4-nitro-1-(3-phenyl-1H-pyrazol-5-yl)-4,5-dihydro-1H-pyrazol-3-yl)(benzofuran-2-yl)methanone,  
 [J] 3-(benzofuran-2-carbonyl)-5-phenyl-1-(3-phenyl-1H-pyrazol-5-yl)-1H-pyrazole-4,4(5H)-dicarbonitrile,  
 [K] (5-(benzo[d][1,3]didxol-4-yl)-4-nitro-1-(3-phenyl-1H-pyrazol-5-yl)-4,5-dihydro-1H-pyrazol-3-yl)(benzofuran-2-yl)methanone,  
 [L] ethyl 1-(3-methoxypheyl)-5-morpholino-4-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 [M] ethyl 1-(3-methoxyphenyl)-4-phenyl-5-(piperazin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxylate, which is optionally bonded to copolystyrol,  
 [N] 1-(3-methoxyphenyl)-4-phenyl-5-(piperazin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid, which is optionally bonded to copolystyrol and  
 [O] ethyl 5-(4-oxo-2,3-diphenyl-4,5-dihydro-2H-pyrazolo[4,3-d]pyridazin-7-yl)-1,4-diphenyl-4,5-dihydro-1H-pyrazole-3-carboxylate,  
 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.  
 
     
     
         2 . A compound according to  claim 1 , characterized in that 
 X is O or S;    R 1  and R 2 , independently of one another, in each case represent an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system; 
 an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 or an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
   R 3  represents an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system; 
 an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group,  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical which together with an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical forms an unsubstituted or at least mono-substituted spirocyclic residue via a common ring atom;  
 a —O—R 6  moiety; a —NR 7 R 8  moiety or a —NR 9 —O—R 10  moiety;  
   R 4  represents F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 or an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 a —O—R 11  moiety; a —S—R 12  moiety; a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
   R 5  represents H; F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 or an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 —O—R 11  moiety; a —S—R 12  moiety; a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
   or R 4  and R 5  together with the bridging carbon atom form an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical;    R 6  represents a hydrogen atom; 
 an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety or a —C(═O)—R 19  moiety;  
   R 7  and R 8 , independently of one another, in each case represent a hydrogen atom; 
 an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical which together with an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical forms an unsubstituted or at least mono-substituted spirocyclic residue via a common ring atom;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least monosubstituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety; a —C(═O)—R 19  moiety; a —S(═O) 2 —R 20  moiety; or a —NR 21 R 22  moiety;  
   R 9  represents a hydrogen atom or an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;    R 10 , R 11 , R 12 , R 13 , R 14 , R 15  and R 20 , independently of one another, in each case represent an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical; 
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bridged by at least one unsubstituted or at least mono-substituted C 1-5  alkylene group and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 or an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
   R 16 , R 17 , R 18  and R 19 , independently of one another, in each case represent an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical; 
 or an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 or an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 and  
   R 21  and R 22 , independently of one another, in each case represent a hydrogen atom; 
 an unsubstituted or at least mono-substituted C 1-16  alkyl radical, C 2-16  alkenyl radical or C 2-16  alkinyl radical;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical or C 4-16  cycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical, which in each case may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical which together with an unsubstituted or at least mono-substituted C 3-16  cycloalkyl radical, C 4-16  cycloalkenyl radical, C 4-16  heterocycloalkyl radical or C 5-16  heterocycloalkenyl radical forms an unsubstituted or at least mono-substituted spirocyclic residue via a common ring atom;  
 an unsubstituted or at least mono-substituted 6- or 10-membered aryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 or an unsubstituted or at least mono-substituted 5- to 14-membered heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or polycyclic ring system and/or may be bonded via an unsubstituted or at least mono-substituted C 1-5  alkylene group, C 2-5  alkenylene group or C 2-5  alkinylene group;  
 whereby  
   the rings of the aforementioned ring system are in each case independently of one another 5- 6- or 7-membered and may in each case independently of one another optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur;    the aforementioned heteroaryl radicals in each case optionally contain 1, 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);    the aforementioned heterocycloalkyl radicals and heterocycloalkenyl radicals in each case optionally contain 1, 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);    optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.    
     
     
         3 . A compound according to  claim 1 , characterized in that R 1  and R 2 , independently of one another, in each case represent a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl, imidazo[2,1-b]thiazolyl, 2H-chromenyl, pyranyl, indazolyl, quinazolinyl, [1,3]-benzodioxolyl, [1,4]-benzodioxanyl, [1,2,3,4]-tetrahydronaphthyl, (2,3)-dihydro-1H-cyclopenta[b]indolyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl and [3,4]-dihydro-2H-benzo[1,4]oxazinyl, which in each case is optionally bonded to the pyrazoline compound of general formula I via the aromatic or heteroaromatic part of the aforementioned radicals and may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , —CH 2 —Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , phenoxy and thiophenyl, whereby the thiophenyl radical can be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl; 
 or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl and norbornenyl, which in each case is optionally bonded to the pyrazoline compound of general formula I via the (hetero)cycloaliphatic part of the aforementioned radicals and    may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—CH 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 .    
     
     
         4 . A compound according to  claim 1 , characterized in that 
 R 3  represents a radical selected from the group consisting of (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydrocarbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2.1]octyl and 8-aza-spiro[4.5]decanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—-Benzyl, benzyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;    a —O—R 6  moiety; a —NR 7 R 8  moiety or a —NR 9 —O—R 10  moiety.    
     
     
         5 . A compound according to  claim 1 , characterized in that 
 R 4  represents F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR  17 ;    a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ;    a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—CH 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, ——NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  , and —N(C 2 H 5 ) 2 ;    a —O—R 11  moiety; a —S—R 12  moiety, a —NH—R 13  moiety or a —NR 14 R 15  moiety.    
     
     
         6 . A compound according to  claim 1 , characterized in that R 4  and R 5  together with the bridging carbon atom form a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 .  
     
     
         7 . A compound according to  claim 1 , characterized in that R 5  represents H; F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a radical selected from the group consisting of methyl, —CF 3 , —CH 2 F, —CF 2 H, —C 2 F 5 , ethyl, —CH 2 —CN, —CH 2 —OH, n-propyl, isopropyl, —CH 2 —CH 2 —CN, —CH 2 —CH 2 —OH, n-butyl, —CH 2 —CH 2 —CH 2 —CN, —CH 2 —CH 2 —CH 2 —OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;    a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl,    a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be bonded via a —(CH 2 )— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , F, Cl and Br;    a —O—R 11  moiety; a —S—R 12  moiety, a —NH—R 13  moiety or a —NR 14 R 15  moiety.    
     
     
         8 . A compound according to  claim 1 , characterized in that R 6  represents a hydrogen atom; a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN, —NO, —NH—C(═O)—CH 3 , —NH—C(═O)—C 2 H 5 , —NH—C(═O)—C(CH 3 ) 3 , —NH—C(═O)—O—CH 3 , —NH—C(═O)—O—C 2 H 5 , —NH—C(═O)—O—C(CH 3 ) 3 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C(CH 3 ) 3 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5  and —C(═O)—C(CH 3 ) 3 ; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo[3.2.1]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—C( 50  O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2 , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl;    a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR1 17  moiety; a —C(═O)—NH—R 18  moiety or a —C(═O)—R 19  moiety.    
     
     
         9 . A compound according to  claim 1  , characterized in that R 7  and R 8 , independently of another, in each case represent a hydrogen atom; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 ,—N(C 2 H 5 ) 2 , —CN and —NO 2 ;    a radical selected from the group consisting of (1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1 ,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2. 1]octyl and 8-aza-spiro[4.5]decanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH2—CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH3)2, —N(C 2 H 5 ) 2 , —O-Benzyl, benzyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;    a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyli, which may be bonded via a —(CH 2 )—, —(CH 2 ) —(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety; a —C(═O)—R 19  moiety; a —S(═O) 2 —R20 moiety; or a —NR 21 R 22  moiety.    
     
     
         10 . A compound according to  claim 1  , characterized in that R 9  represents hydrogen or an alkyl radical selected from the group consisting of methyl, ethyl and n-propyl.  
     
     
         11 . A compound according to  claim 1  , characterized in that R 10 , R 11 , R 12 , R 13 , R 14 , R 15  and R 20 , independently of another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo[3.2.1]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )—or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(—O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N (C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(—O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH2CH 3 , —O—CH(CH 3 ) 2 , —O—CH2—CH2—CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 .    
     
     
         12 . A compound according to  claim 1  , characterized in that R 16 , R 17 , R 18  and R 19 , independently of one another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NH—C(═O)—CH 3 , —NH—C(═O)—C 2 H 5 , —NH—C(═O)—C(CH 3 ) 3 , —NH—C(═O)—O—CH 3 , —NH—C(═O)—O—C 2 H 5 , —NH—C(═O)—O—C(CH 3 ) 3 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C(CH 3 ) 3 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —OH, —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5  and —C(═O)—C(CH 3 ) 3 ; 
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH,CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2,  —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—C(═O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2 , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl.    
     
     
         13 . A compound according to  claim 1  , characterized in that R 21  and R 22,  independently of another, in each case represent hydrogen; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, 5 isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F. Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ;    a radical selected from the group consisting of (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1 ,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2.1]octyl and 8-aza-spiro[4.5]decanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;    or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 ) —(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl,.n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2,  —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 .    
     
     
         14 . A compound according to  claim 1  , characterized in that 
 X is S or O;    R 1  and R 2 , independently of one another, in each case represent a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl); thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyli imidazo[2,1-b]thiazolyl, 2H-chromenyl, pyranyl, indazolyl, quinazolinyl, [1,31-benzodioxolyl, [1,4]benzodioxanyl, [1,2,3,4]-tetrahydronaphthyl, (2,3)-dihydro-lH-cyclopenta[b]indolyl, (1 ,2,3,4]-tetrahydroquinolinyl, [1 ,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl and [3,4] dihydro-2H-benzo[1,4]oxazinyl, which in each case is optionally bonded to the pyrazoline compound of general formula I via the aromatic or heteroaromatic part of the aforementioned radicals and may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , —CH 2 —Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(O) C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH3, —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , phenoxy and thiophenyl, whereby the thiophenyl radical can be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl;    or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyli, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyli, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl and norbornenyl, which in each case is optionally bonded to the pyrazoline compound of general formula I via the (hetero)cycloaliphatic part of the aforementioned radicals and may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2,  —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    R 3  represents a radical selected from the group consisting of (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2W-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1 ,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2.1]octyl and 8-aza-spiro[4.5]decanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O—) 2 —CH 3 , —S(═O—) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O-Benzyl, benzyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl; 
 a —O—R 6  moiety; a —NR 7 R 8  moiety or a —NR 9 —O—R 10  moiety;  
   R 4  represents F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 7 ; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3,  —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 a —O—R 11  moiety; a —S—R 12  moiety, a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
   R 5  represents H, F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a radical selected from the group consisting of methyl, —CF 3 , —CH 2 F, —CF 2 H, —C 2 F 5 , ethyl, —CH 2 —CN, —CH 2 —OH, n-propyl, isopropyl, —CH 2 —CH 2 —CN, —CH 2 —CH 2 —OH, n-butyl, —CH 2 —CH 2 —CH 2 —CN, —CH 2 —CH 2 —CH 2 —OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;  
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be bonded via a —(CH 2 )-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , F, Cl and Br;  
 a —O—R 11  moiety; a —S—R 12  moiety, a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
   R 4  and R 5  together with the bridging carbon atom form a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;    R 6  represents a hydrogen atom; a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN, —NO, —NH—C(═O)—CH 3 , —NH—C(═O)—C 2 H 5 , —NH—C(═O)—C(CH 3 ) 3 , —NH—C(═O)—O—CH 3 , —NH—C(═O)—O—C 2 H 5 , —NH—C(═O)—O—C(CH 3 ) 3 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C(CH 3 ) 3 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5  and —C(═O)—C(CH 3 ) 3 ; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo[3.2.1]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH—CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SOF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O—)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—C(═O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2  , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety or a —C(═O)—R 19  moiety;  
   R 7  and R 8 , independently of another, in each case represent a hydrogen atom; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ;  
 a radical selected from the group consisting of (1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2.1]octyl and 8-aza-spiro[4.5]decanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 (substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O-Benzyl, benzyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety; a —C(═O)—R 19  moiety; a —S(═O) 2 —R 20  moiety; or a —NR 21 R 22  moiety;  
   R 9  represents hydrogen or an alkyl radical selected from the group consisting of methyl, ethyl and n-propyl.    R 10 , R 11 , R 12 , R 13 , R 14 , R 15  and R 20 , independently of another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo[3.2.1]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═—CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —C—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O—)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
   R 16 , R 17 , R 18  and R 19 , independently of one another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NH—C(═O)—CH 3 , —NH—C(═O)—C 2 H 5 , —NH—C(═O)—C(CH 3 ) 3 , —NH—C(═O)—O—CH 3 , —NH—C(═O)—O—C 2 H 5 , —NH—C(═O)—O—C(CH 3 ) 3 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C(CH 3 ) 3 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —OH, —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5  and —C(═O)—C(CH 3 ) 3 ; 
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—C(═O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2 , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl;  
 and  
   R 21  and R 22,  independently of another, in each case represent hydrogen; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ;  
 a radical selected from the group consisting of (2,3)-dihydro-1H-cyclopenta[b]indolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl, (1,3)-dioxolanyl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, (1,2,3,4)-tetrahydroquinoxazlinyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, norbornenyl, 8-aza-bicyclo[3.2.1]octyl and 8-aza-spiro[4.5]decanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —O—CH 2 —O—CH 3 , —O—CH 2 —CH 2 —O—CH 3 , —O—CH 2 —O—C 2 H 5 , —C(OCH 3 )(C 2 H 5 ) 2 , —C(OCH 3 )(CH 3 ) 2 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;  
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2  —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O) NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O) C 2 H 5  —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH2, —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.  
   
     
     
         15 . A compound according to  claim 1  , characterized in that 
 X is O or S;    R 1  represents a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyI, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo[2,1-b]thiazolyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , —CH 2 —Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —NO 2 , —OH, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br, I, —CN, —OCF 3,  —SCF 3 , —SCF 2 H, —SCFH 2 , phenoxy and thiophenyl, whereby the thiophenyl radical can be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl; 
 or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, —CN, —OCF 3,  —SCF 3 , —SCF 2 H and —SCFH 2 ;  
   R 2  represents a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrinidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo[2,1-b]thiazolyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —OH, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H and —SCFH 2 ; 
 or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H and —SCFH 2 ;  
   R 3  represents a radical selected from the group consisting of                                          which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH— groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;    a —O—R 6  moiety, a —NR 7 R 8  moiety or a —NR 9 —O—R 10  moiety;      R 4  represents F; Cl; Br; I; —CN; —NO 2 ; —NC; —OH; —NH 2 ; —SH; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a radical selected from the group consisting of methyl, —CF 3 , —CH 2 F, —CF 2 H, —C 2 F 5 , ethyl, —CH 2 —CN, —CH 2 —OH, n-propyl, isopropyl, —CH 2 —CH 2 —CN, —CH 2 —CH 2 —OH, n-butyl, —CH 2 —CH 2 —CH 2 —CN, —CH 2 —CH 2 —CH 2 —OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be bonded via a —(CH 2 )— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , F, Cl and Br;  
 a —O—R 11  moiety; a —S—R 12  moiety, a —NH—R 13  moiety or a —NR 14 R 15  moiety;  
   R 5  represents H; F; Cl; Br;—C(═O)—OH; —C(═O)—OR 17 ; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl;    or R 4  and R 5  together with the bridging carbon atom form a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl;    R 6  represents a hydrogen atom; a radical selected from the group consisting of methyl, —CF 3 , —CH 2 F, —CF 2 H, —CH 2 —O—CH 3 , —C 2 F 5 , —CH 2 —CH 2 —F, ethyl, —CH 2 —CN, —CH 2 —OH, n-propyl, isopropyl, —CH 2 —CH 2 —CN, —CH 2 —CH 2 —OH, —CH 2 —CH 2 —OCH 3 , n-butyl, —CH 2 —CH 2 —CH 2 —CN, —CH 2 —CH 2 —CH 2 —OH, —CH 2 —CH 2 —CH2O—CH 3 , isobutyl, sec-butyl, tert-butyl, n-pentyl, —CH 2 —CH 2 —CH 2 —CH 2 —O—CH 3 , 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl and n-octyl; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, imidazolidinyl, azepanyl, 8-aza-bicyclo[3.2.1 ]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3  and —O—C(CH 3 ) 3 ;  
 a radical selected from the group consisting of pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and imidazolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH=CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , F, Cl, Br, I, —O—C(═O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2 , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl;  
 a —P(═O)(OR 16 ) 2  moiety; a —C(═O)—OR 17  moiety; a —C(═O)—NH—R 18  moiety or a —C(═O)—R 19  moiety;  
   R 7  and R 8 , independently of another, in each case represent a hydrogen atom; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, —CH 2 —NH 2 , —CH 2 —N(CH 3 ) 2 , —CH 2 —CH—NH 2 , —CH 2 —CH 2 —N(CH 3 ) 2 , —CH 2 —CH 2 —N(C 2 H 5 ) 2 , —CH 2 —CH 2 —CH 2 —NH 2 , —CH 2 —N(CH 3 ) 2  and —CH 2 —CH 2 —CH 2 —N(C 2 H 5 ) 2 ;  
 a radical selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, [1,2,3,4]-tetrahydronaphthyl and bicyclo[2.2.1]heptyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituient(s) independently selected from the group consisting of —OH, —O—CH 3 , —O—C 2 H 5 , —O-Benzyl, benzyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl and n-hexyl;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;  
 a —S(═O) 2 —R 20  moiety;  
 a —NR 21  R 22  moiety;  
 a radical selected from the group consisting of  
                                                         
 which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH— groups, optionally via a —(CH 2 )— or —(CH 2 )—(CH 2 )— group, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;  
   R 9  represents hydrogen;    R 10 , R 11 , R 12 , R 13 , R 14 , R 15  and R 20 , independently of another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6-methyl)-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of —OH, F, Cl, Br, I, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —CN and —NO 2 ; 
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo[3.2.1]octyl and diazepanyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH 3 , —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ;  
   R 16 , R 17 , R 18  and R 19 , independently of one another, in each case represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethinyl, propinyl, n-butinyl, n-pentinyl and n-hexinyl, which may optionally be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NH—C(═O)—CH 3 , —NH—C(═O)—C 2 H 5 , —NH—C(═O)—C(CH 3 ) 3 , —NH—C(═O)—O—CH 3 , —NH—C(═O)—O—C 2 H 5 , —NH—C(═O)—O—C(CH 3 ) 3 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C(CH 3 ) 3 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —OH, —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5  and —C(═O)—C(CH 3 ) 3 ; 
 or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—CH 2 —CH 2 —CH 2 —CH 3 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 —CH 2 —CH 2 —CH 3 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —SCF 2 H, —SCFH 2 , —OH, —SH, —NO 2 , —CHO, —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—C(CH 3 ) 3 , —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—NH—C 3 H 7 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O)—CH 3 , —S(═O)—C 2 H 5 , —S(═O)—C 3 H 7 , —S(═O) 2 —CH —S(═O) 2 —C 2 H 5 , —S(═O) 2 —C 3 H 7 , —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —O—C(═O)—CH 3 , —O—C(═O)—C 2 H 5 , —O—C(═O)—CH(CH 3 ) 2 , —O—C(═O)—CH 2 —CH 2 —CH 3 , —CH 2 —N(CH 3 ) 2 , —(CH 2 )—N(C 2 H 5 ) 2 , —CH 2 —N(C 3 H 7 ) 2 , —CH 2 —N(C 4 H 9 ) 2 , —CH 2 —N(CH 3 )(C 2 H 5 ) and —(CH 2 )-morpholinyl;  
 and  
   R 21  and R 22,  independently of another, in each case represent hydrogen; 
 a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2-(6-methyl)-heptyl, 2-(5-methyl)-heptyl, 2-(5-methyl)-hexyl, 2-(4-methyl)-hexyl, 2-(7-methyl)-octyl; 2-(6methyl)-octyl, —CH 2 —NH 2 , —CH—N(CH 3 ) 2 , —CH 2 —CH—NH 2 , —CH 2 —CH 2 —N(CH 3 ) 2 , —CH 2 —CH 2 —N(C 2 H 5 ) 2 , —CH 2 —CH 2 —CH 2 —NH 2 , —CH 2 —CH 2 —CH 2 —N(CH 3 ) 2  and —CH 2 —CH 2 —CH 2 —N(C 2 H 5 ) 2 ;  
 a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl and n-hexyl;  
 a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )— or —CH═CH— group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;  
 or a radical selected from the group consisting of  
                                       
 which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH— groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;  
 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.  
   
     
     
         16 . A compound according to  claim 1  , characterized in that 
 x is O or S;    R 1  represents a radical selected from the group consisting of phenyl and thienyl (thiophenyl), which may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —OH, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br and I;    R 2  represents a phenyl radical, which may be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of —OH, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br and I;    R 3  represents a radical selected from the group consisting of                                            which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH— groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;    a —OR 6 — moiety or a —NR 7 R 8  moiety;    R 4  represents F; Cl; Br; I; —OH, —CN; —C(═O)—H; —C(═O)—OH; —C(═O)—OR 17 ; 
 a radical selected from the group consisting of methyl, —CF 3 , —CH 2 F, —CF 2 H, —C 2 F 5 , ethyl, —CH 2 —CN, —CH 2 —OH, n-propyl, isopropyl, —CH 2 —CH 2 —CN, —CH 2 —CH 2 —OH, n-butyl, —CH 2 —CH 2 —CH 2 —CN, —CH 2 —CH 2 —CH 2 —OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;  
 a benzyl radical or a —O—R 11  moiety;  
   R 5  represents H; F; Cl; Br;—C(═O)—OH; —C(═O)—OR 17 ; or a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl and n-butyl; 
 or R 4  and R 5  together with the bridging carbon atom form a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl;  
   R 6  represents a hydrogen atom; a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl and tert-butyl or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;    R 7  represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl;    R 8  represents a radical selected from the group consisting of [1,2,3,4]-tetrahydronaphthyl, bicyclo[2.2.1]heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl, which may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )— or —(CH 2 )—(CH 2 )—(CH 2 )-group and/or subsituted with 1, 2, 3 or 4 substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, —OH, —O—CH 3  and —O—C 2 H 5 ; 
 or a radical selected from the group consisting of  
                                       
 which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;  
 and  
   R 11  and R 17 , independently of one another, each represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl and neo-pentyl;    optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.    
     
     
         17 . A compound or salt according to  claim 1  selected from the group consisting of 
 [1] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide hydro-chloride    [2] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide hydro-chloride    [3] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide    [4] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide    [5] cis-[5-(4-Chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl]-(4-cyclohexyl-piperazin-1-yl)-methanone    [6] trans-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl]-(4-cyclohexyl-piperazin-1-yl)-methanone    [7] cis-5-(4Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid pyrrolidin-1-ylamide    [8] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid pyrrolidin-1-ylamide    [9] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (4-methyl-piperidin-1-yl)-amide    [10] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (4-methyl-piperidin-1-yl)-amide    [11] cis-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl]-piperidin-1-yl-methanone    [12] trans-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl]-piperidin-1-yl-methanone    [13] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide    [14] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (hexahydro-cyclopenta-[c]py-rrol-2-yl)-amide    [15] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (2,3-dihydro-indol-1-yl)-amide    [16] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (2,3-dihydro-indol-1-yl)-amide    [17] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid cyclobutylamide    [18] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid cyclohexyl methyl-amide    [19] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [20] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [21] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [22] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [23] cis-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid methyl ester    [24] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid methyl ester    [25] cis-5-(4Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester    [26] trans-5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester    [27] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid cyclohe-xyl ester    [28] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,4-dimethyl-4,5-dihydro-1-H-pyrazole-3-carboxylic acid    [29] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,4-dimethyl-4,5-dihydro-1-H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [30] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [31] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [32] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [33] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-(2-hydroxy-ethyl)-4,5-di-hydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [34] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-(2-hydroxy-ethyl)-4,5-di-hydro-1H-pyrazole-3-carboxylic acid    [35] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-fluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [36] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-fluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [37] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [38] 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [39] 5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    [40] 5-(4-Chloro-phenyl)-4-cyano-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [41] 1-(2,4-Dichloro-phenyl)-5-(4-fluoro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [42] 1-(2,4-Dichloro-phenyl)-4-ethyl-5-(4-fluoro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [43] 1-(2,4-Dichloro-phenyl)-5-(4-fluoro-phenyl)-4,4-dimethyl-4,5-dihydro-1-H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [44] 1-(2,4-Dichloro-phenyl)-5-(4-fluoro phenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [45] 1-(2,4-Dichloro-phenyl)-5-(4-fluoro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide [46] 1-(2,4-Dichloro-phenyl)-5-(4-fluoro-phenyl)-4-(2-hydroxy-ethyl)-4,5-dihydro-1pyrazole-3-carboxylic acid piperidin-1-ylamide    [47] 1-(2,4-Dichloro-phenyl)-4-fluoromethyl-5-(4-fluoro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [48] 1-(2,4-Dichlorophenyl)-5-(4-fluoro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [49] 4-Cyano-1-(2,4-dichloro-phenyl)-5-(4-fluoro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [50] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide [51] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [52] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-yiamide    [53] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [54] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [55] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-(2-hydroxy-ethyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [56] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-fluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [57] 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [58] 5-(4-Bromo-phenyl)-4-cyano-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [59] cis-5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [60] trans-5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [61] cis-5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [62] trans-5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [63] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [64] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [65] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [66] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-(2-hydroxy-ethyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [67] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-fluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [68] 5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [69] 5-(5-Chloro-thiophen-2-yl)-4-cyano-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [70] cis-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [71] trans-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [72] cis-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [73] trans-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [74] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-di-chloro-phenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [75] cis-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [76] trans-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [77] cis-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [78] trans-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [79] 5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [80] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [81] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-di-chloro-phenyl)-4-hydroxy-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [82] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-di-chloro-phenyl)-4-(2-hydroxy-ethyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [83] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-di-chloro-phenyl)-4-fluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [84] 5-(5-Bromo-thiophen-2-yl)-1-(2,4-di-chloro-phenyl)-4-formyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [85] 5-(5-Bromo-thiophen-2-yl)-4-cyano-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    [86] cis-5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [87] trans-[5-(5-Chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl]-piperidin-1-yl-methanone    [88] cis-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl) 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [89] trans-5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [90] cis-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [91] trans-5-(4-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid,    92 (+)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    93 (−)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    94 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    95 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    96 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide hydrochloride    97 trans-5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide hydrochloride    98 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    99 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    100 cis-5-(4-chlorophenyl)-N-(4-cyclopentylpiperazin-1-yl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    101 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-morpholino-4,5-dihydro-1H-pyrazole-3-carboxamide    102 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(4-methylpiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    103 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    104 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-amide    105 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (1H,3H-benzo[de]isoquinolin-2-yl)-amide    106 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((R)-2-(methoxymethyl)pyrrolidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    107 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((S)-2-(methoxymethyl)pyrrolidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    108 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide hydrochloride    109 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    110 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    111 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    112 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    113 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(2-methylindolin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    114 cis-5-(4chlorophenyl)-N-(cyclohexylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    115 cis-5-(4-chlorophenyl)-N-(cycloheptylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    116 cis-5-(4-chlorophenyl)-N-cyclododecyl-1-( 2,4- dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    117 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    118 cis-N-(4-tert-butylcyclohexyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    119 cis-5-(4-chlorophenyl)-N-cyclooctyl-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    120 cis-N-(azocan-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    121 cis-N-(azocan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    122 cis-azocan-1-yl(cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazol-3-yl)methanone    123 cis-5-(4-chlorophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    124 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cycloheptyl-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    125 trans-5-(4-chlorophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    126 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cycloheptyl-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    127 cis-5-(4-chlorophenyl)-N-(cyclohexylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    128 (+)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    129 (−)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    130 (−)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    131 (+)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    132 (+)-cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    133 (−)-cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    134 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(4-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    135 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(4-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    136 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(3-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    137 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(3-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    138 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(2-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    139 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(2-hydroxypiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    140 cis-5-(4-chlorophenlyl)-1-(2,4dichlorophenyl)-4-methyl-N-(4-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    141 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(4-oxopiperidin-1yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    142 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(3-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    143 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(-3oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    144 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(3,4-dihydropyridin-1(2H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    145 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(3,4-dihydropyridin-1(2H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    146 cis-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-N-(5,6-dihydropyridin-1(2H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    147 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(5,6-dihydropyridin-1(2H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    148 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    149 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    150 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-py-razole-3-carboxylic acid cyclohexyl ester    151 N-(azepan-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    152 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4,4-dimethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    153 N-(azepan-1-yl)-1-(2-chlorophehyl)-5-(4-chlorophenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    154 cis-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    155 trans-5-(4-Chloro-phenyl)-1-(2,4-dichlorophenyl)-4-trifluoromethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide    156 cis-N-(azepan-1-yl)-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    157 trans-N-(azepan-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    158 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(piperidin-1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    159 trans 1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(piperidin-1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    160 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(piperidin-1-ylcarbamoyl)-4,5-dihydro-1H-pyrazole-4-carboxylic acid    161 5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4,4-difluoro-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    162 cis-5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    163 cis-N-(azepan-1-yl)-5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    164 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-cyano-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    165 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-cyano-4,5-dihydro-1H-pyrazole-3-carboxamide    166 trans-5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    167 trans-N-(azepan-1-yl)-5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    168 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-cyano-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    169 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-4,5-dihydro-1-pyrazole-3-carboxylic acid    170 trans-1-(2 chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    171 cis-5-(4chlorophenyl)-1-(2,4dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    172 trans-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    173 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3 carboxamide    174 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    175 cis-N-(azepan-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    176 trans-N-(azepan-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    177 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    178 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    179 cis-5-(4-chlorophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    180 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cycloheptyl-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    181 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    182 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    183 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(indolin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    184 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-N-(indolin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    185 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    186 trans-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    187 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    188 trans-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    189 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    190 trans-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    191 cis-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    192 cis-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    193 cis-5-(4-bromophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    194 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-cycloheptyl-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    195 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    196 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-ethyl-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    197 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(indolin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    198 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-ethyl-N-(indolin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    199 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    200 trans-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    201 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    202 trans-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    203 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    204 trans-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    205 cis 5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    206 trans-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    207 cis-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2,4dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    208 trans-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    209 cis-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    210 cis-N-(azepan-1-yl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    211 cis-5-(4-bromophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    212 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-cycloheptyl-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    213 cis-5-(4-bromophenyl)-1-(2,4dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    214 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    215 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    216 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    217 (+)-cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    218 (−)-cis-5-(4bromophenyl)-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    219 (+)-cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    220 (−)-cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    221 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    222 trans-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    223 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    224 trans-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    225 cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    226 trans-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    227 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    228 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    229 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    230 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    231 cis-N-cycloheptyl-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    232 cis-1-(2-chlorophenyl)-N-cycloheptyl-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    233 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    234 cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    235 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    236 cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-N-(indolin- -yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    237 (+)-cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    238 (−)-cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    239 (+)-cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    240 (−)-cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    241 cis-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    242 trans-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    243 cis-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    244 trans-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    245 cis-1-(2-chlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    246 trans-1-(2-chlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    247 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    248 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    249 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    250 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    251 cis-N-cycloheptyl-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    252 cis-1-(2-chlorophenyl)-N-cycloheptyl-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    253 cis-1-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    254 cis-1-(2-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    255 cis-1-(2,4-dichlorophenyl)-N-(indolin-1-yl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    256 cis-1-(2-chlorophenyl)-N-(indolin-1-yl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    257 (+)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    258 (−)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    259 (+)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    260 (−)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-iodophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    261 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    262 trans-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    263 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    264 trans-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    265 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    266 (+)-cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    267 (−)-cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    268 trans-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    269 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    270 trans-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    271 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    272 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    273 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    274 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    275 cis-N-cycloheptyl-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    276 cis-1-(2-chlorophenyl)-N-cycloheptyl-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    277 cis-1-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    278 cis-1-(2-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    279 cis-1-(2,4-dichlorophenyl)-N-(indolin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    280 cis-1-(2-chlorophenyl)-N-(indolin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    281 (+)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    282 (−)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    283 (+)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    284 (−)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    285 cis-1-(2,4-dichlorophenyl)-N-(4-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    286 cis-1-(2-chlorophenyl)-N-(4-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    287 cis-1-(2,4-dichlorophenyl)-N-(3-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    288 cis-1-(2-chlorophenyl)-N-(3-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    289 cis-1-(2,4-dichlorophenyl)-N-(2-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    290 cis-1-(2-chlorophenyl)-N-(2-hydroxypiperidin-1-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    291 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(4-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    292 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(4-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    293 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(3-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    294 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(3-oxopiperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    295 cis-1-(2,4-dichlorophenyl)-N-(3,4-dihydropyridin-1(2H)-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    296 cis-1-(2-chlorophenyl)-N-(3,4-dihydropyridin-1(2H)-yl)-5-(4methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    297 cis-1-(2,4-dichlorophenyl)-N-(5,6-dihydropyridin-1(2H)-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    298 cis-1-(2-chlorophenyl)-N-(5,6-dihydropyridin-1(2H)-yl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    299 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide 300 trans-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    301 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    302 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    303 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    304 trans-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin1-yl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    305 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,4-dimethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    306 N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,4-dimethyl-4,5-dihydro-1H-pyrazole-3-carboxamide    307 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4,4-dimethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    308 1-(2,4-dichlorophenyl)-4-formyl-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    309 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-3-(piperidin-1-ylcarbamoyl)-4,5-dihydro-1H-pyrazole-4-carboxylic acid    310 1-(2,4-dichlorophenyl)-4-(2-hydroxyethyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    311 1-(2,4-dichlorophenyl)-4-(fluoromethyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    312 cis-4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    313 trans-4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    314 cis-N-(azepan-1-yl)-4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    315 trans-N-(azepan-1-yl)-4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    316 cis-1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    317 trans-1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    318 1-(2,4-dichlorophenyl)-4-hydroxy-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    319 1-(2-chloropheny!)-4,4-difluoro-5-(4methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    320 1-(2-chlorophenyl)-44formyl-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    321 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-3-(piperidin-1-ylcarbamoyl)-4,5-dihydro-1H-pyrazole-4-carboxylic acid    322 1-(2-chlorophenyl)-4-(2-hydroxyethyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    323 1-(2-chlorophenyl)-4-(flUoromethyl)-5-(4methoxyphenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    324 1-(2-chlorophenyl)-4-hydroxy-5-(4-methoxyphenyl)-N-(piperidin- 1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    325 cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    326 trans-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    327 cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    328 trans-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    329 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    330 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    331 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    332 transN-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    333 cis-N-cycloheptyl-1-(2,4dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    334 cis-1-(2-chlorophenyl)-N-cycloheptyl-5-(4-ethoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    335 cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    336 cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    337 cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    338 cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    339 (+)-cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    340 (−)-cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    341 (+)-cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    342 (−)-cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    343 cis-1-(24dichlorophenyl-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    344 trans-1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    345 cis-1-(2-chlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    346 trans-1-(2-chlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    347 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4′methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    348 trans-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    349 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    350 trans-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    351 cis-N-cycloheptyl-1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    352 cis-1-(2-chlorophenyl)-N-cycloheptyl-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    353 cis-1-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    354 cis-1-(2-chlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    355 cis-1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    356 cis-1-(2-chlorophenyl)-5-(4-hydroxyphenyl)-N-(indolin-1-yl)-4-methyl4,5-dihydro-1H-pyrazole-3-carboxamide    357 (+)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    358 (−)-cis-1-(2,4-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    359 (+)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    360 (−)-cis-1-(2-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl)-5-(4-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    361 cis-5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    362 trans-5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    363 cis-1-(2 chlorophenyl)-5-(5-chlorothiophen 2-yi)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    364 trans-1-(2-chlorophenyl)-5-(5-chlorothiophen-2-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    365 cis-5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    366 trans-5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-ethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    367 cis-1-(2,4-dichlorophenyl)-4-methyl-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid    368 trans-1-(2,4-dichlorophenyl)-4-methyl-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid    369 cis-1(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    370 trans-1-(2,4dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    371 cis-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    372 trans-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    373 cis-1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    374 trans-1-(2,4dichlorophenyl)-4-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    375 cis-1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    376 trans-1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    377 cis-1-(2-chlorophenyl)-4-methyl-5-phenyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    378 trans-1-(2-chlorophenyl)-4-methyl-5-phenyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    379 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide hydrochloride    380 trans-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    381 cis-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    382 trans-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    383 cis-N-(azepan-1-yl)-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carbothioamide    384 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carbothioamide    385 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    386 trans-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    387 cis-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    388 trans-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    389 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    390 trans-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    391 cis-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    392 trans-1-(2-chlorophenyl)-5-(44luorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    393 cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    394 cis-N-(azepan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carbothioamide    395 trans-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    396 cis-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N (piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    397 cis-N-(azepan-1-yl)-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carbothioamide    398 trans-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    399 cis-1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    400 trans1-(2,4-dichlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    401 cis-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    402 trans-1-(2-chlorophenyl)-5-(4-ethoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    403 cis-1(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide 404 trans-1-(2,4dichoropheno)-5-(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    405 cis-1-(2-chlorophenyl)-5-(4 hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    406 trans-1-(2-chlorophenyl)-5(4-hydroxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carbothioamide    407 7-(4-Chloro-phenyl)-6-(2,4-dichlorophenyl)-5,6 diaza-spiro[2.4]hept-4-ene-4-carboxylic acid piperidin-1-ylamide    408 6-(2,4-Dichloro-henyl)-7-(4-methoxy-phenyl)-5,6-diaza-spiro[2.4]hept-4-ene-4-carboxylic acid piperidin-1-ylamide    409(+)-cis-N-N-((1S,2S)-2-(benzyloxy)cyclohexyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    [410] cis-1-(2,4-dichlorophehyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    [411] cis-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-I H-pyrazole-3-carboxamide    [412] (4R,5S)-1-(2,4dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [413] cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [414] cis-N-(azepan-1-yl)1-(2,4-dichlorophenyl)-5-(4fluorophenyl)-4methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    415 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(indolin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    416 trans-ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-3-carboxylate    417 cis-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-4ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    418 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    419(−)-cis-5-(4-chlorophenyl)-1-(2,4-dichlorophen yl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    420(+)-cis-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    421 trans-ethyl 1-(2,4-dichlorophenyl)-4-methyl-5phenyl-4,5-dihydro-H-pyrazole-3-carboxylate    422 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    423 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(3-methylcyclohexyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    424 cis-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-N-(2-methylcyclohexyl)-4,5-dihydro-1H-pyrazole-3-carboxamide    426 trans-5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    427 cis-5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    428 cis-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    [429] 1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid    [430] cis-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride    [431] trans-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    432 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    434 cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide    436(+)-cis-N-((1S,2S)-2-(benzyloxy)cyclohexyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    437(−)-cis-N-((1R,2R)-2-(benzyloxy)cyclohexyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    438 cis-N-(azocan-1-yl)-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    439 cis-N-(azocan-1-yl)-1-(2-chlorophenyl)-5-(4methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    440 cis-N-(azocan-1-yl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    441 cis-N-(azocan-1-yl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    442 cis-N-(azocan-1-yl)-1-(2,4-dichlorophenyl)-5-(4fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    443 cis-N-(azocan-1-yl)-1-(2-chlorophenyl)-5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide    444(+)-cis-5(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide hydrochloride    445(−)-cis- (4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid azepan-1-ylamide hydrochloride    [446] cis-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide    [447] cis-5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide    [448] cis-N-(azepan-1-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide    [449] cis-N-(azepan-1-yl)-5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide    [450] cis-1-(2,4-dichlorophenyl)-5-(4methoxyphenyl)-4methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide and    [451] cis-1-(2-chlorophenyl)-5-(4-rethoxyphenyl)-4methyl-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide N-oxide;    optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.    
     
     
         18 . Process for the preparation of a compound of general formula I according to  claim 1 , wherein R 5  represents hydrogen, characterized in that at least one compound of general formula II,  
       
         
           
           
               
               
           
         
         wherein R 1 , X and R 4  have the meaning according to  claim 1 , is reacted with at least one compound of general formula III,  
         
           
             
             
                 
                 
             
           
         
         or a corresponding salt thereof, wherein R 2  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one acid, to yield at least one compound of general formula IV,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X, R 2  and R 4  have the meaning according to  claim 1 , which is optionally isolated and/or purified,  
         and at least one compound of general formula IV is reacted with an activating agent in a reaction medium, optionally in an inert atmosphere, to yield at least one compound of general formula V,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X, R 2  and R 4  have the meaning according to  claim 1  and A represents a leaving group, which is optionally purified and/or isolated,  
         and at least one compound of general formula V is reacted with at least one compound of general formula R 3 —H, wherein R 3  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base selected from the group consisting of diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine and N-methylmorpholine, to yield at least one compound of general formula I, wherein R 1 , R 2 , X, R 3  and R 4  have the meaning according to  claim 1  and R 5  represents hydrogen, which is optionally purified and/or isolated;  
         or at least one compound of general formula IV is reacted with at least one compound of general formula R 3 —H, wherein R 3  represents a —NR 7 R 8  moiety, whereby R 7  and R 8  have the meaning according to  claim 1 , in a reaction medium, in the presence of at least one coupling agent, optionally in the presence of at least one base, to yield at least one compound of general formula I, wherein R 1 , R 2 , X and R 4  have the meaning according to  claim 1 , R 3  represents a —NR 7 R 8  moiety and R 5  represents hydrogen, which is optionally purified and/or isolated.  
       
     
     
         19 . Process for the preparation of a compound of general formula I according to  claim 1 , wherein R 5  represents hydrogen, characterized in that at least one compound of general formula R 1 —C(═O)—H (general formula VIl), wherein R 1  has the meaning according to  claim 1 , is reacted with at least one compound of general formula VI,  
       
         
           
           
               
               
           
         
         wherein R 4  and X have the meaning according to  claim 1  and R′ represents a linear or branched C 1-6 -alkyl radical, a potassium cation or a sodium cation, in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base, to yield at least one compound of general formula II,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X and R 4  have the meaning according to  claim 1 , which is optionally purified and/or isolated,  
         and at least one compound of general formula II is reacted with an activating agent in a reaction medium, optionally in an inert atmosphere, to yield at least one compound of general formula VIII,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X and R 4  have the meaning according to  claim 1  and A represents a leaving group, which is optionally purified and/or isolated,  
         and at least one compound of general formula VII is reacted with at least one compound of general formula R 3 —H, wherein R 3  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base selected from the group consisting of diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine and N-methylmorpholine, to yield at least one compound of general formula IX,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X, R 3  and R 4  have the meaning according to  claim 1 , which is optionally purified and/or isolated;  
         or at least one compound of general formula II is reacted with at least one compound of general formula R 3 —H, wherein R 3  represents a —NR 7 R 8  moiety, whereby R 7  and R 8  have the meaning according to  claim 1 , in a reaction medium, in the presence of at least one coupling agent, optionally in the presence of at least one base, to yield at least one compound  
         general formula IX, wherein R 3  represents a —NR 7 R 8  moiety, which is optionally purified and/or isolated,  
         and at least one compound of general formula IX is reacted with at least one compound of general formula III,  
         
           
             
             
                 
                 
             
           
         
         wherein R 2  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one acid, to yield at least one compound of general formula I, wherein R 1 , X, R 2 , R 3  and R 4  have the meaning according to  claim 1  and R 5  represents hydrogen, which is optionally purified and/or isolated.  
       
     
     
         20 . Process for the preparation of a compound of general formula I according to  claim 1 , wherein R 5  is unlike hydrogen, characterized in that at least one compound of general formula R 1 —C(═O)—H (general formula VII), wherein R 1  has the meaning according to  claim 1 , is reacted with at least one compound of general formula VIb,  
       
         
           
           
               
               
           
         
         wherein R 4 , R 5  and X have the meaning according to  claim 1 , R 5  is unlike hydrogen and R′ represents a linear or branched C 1-6 -alkyl radical, a potassium cation or a sodium cation, in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base, to yield at least one compound of general formula XXXI,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , R 4 , R 5  and X have the meaning according to  claim 1 , R 5  is unlike hydrogen, and R′ represents a linear or branched C 1-6 -alkyl radical, a potassium cation or a sodium cation,  
         and at least one compound of general formula XXXXI is reacted with a reagent, that transforms a hydroxyl group into a leaving group, preferably with a reagent selected from the group consisting of methansulfonylchloride and toluolsulfonylchloride, in a reaction medium, optionally in the presence of at least one base, preferably in the presence of at least one base selected from the group consisting of triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine, to yield a compound of general formula XXXXII,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , R 4 , R 5  and X have the meaning according to  claim 1 , R 5  is unlike hydrogen, R′ represents a linear or branched C 1-6 -alkyl radical, a potassium cation or a sodium cation, and LG is a leaving group, preferably mesyl or tosyl;  
         and at least one compound of general formula XXXXII is reacted with at least one compound of general formula III,  
         
           
             
             
                 
                 
             
           
         
         or a corresponding salt thereof, wherein R 2  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one acid, to yield at least one compound of general formula lVb,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X, R 2 , R 4  and R 5  have the meaning according to  claim 1  and R 5  is unlike hydrogen, which is optionally isolated and/or purified,  
         and at least one compound of general formula lVb is reacted with an activating agent in a reaction medium, optionally in an inert atmosphere, to yield at least one compound of general formula Vb,  
         
           
             
             
                 
                 
             
           
         
         wherein R 1 , X, R 2 , R 4  and R 5  have the meaning according to  claim 1 , R 5  is unlike hydrogen and A represents a leaving group, which is optionally purified and/or isolated,  
         and at least one compound of general formula Vb is reacted with at least one compound of general formula R 3 —H, wherein R 3  has the meaning according to  claim 1 , in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base selected from the group consisting of diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine and N-methylmorpholine, to yield at least one compound of general formula I, wherein R 1 , R 2 , X, R 3 , R 4  and R 5  have the meaning according to  claim 1  and R 5  is unlike hydrogen, which is optionally purified and/or isolated;  
         or at least one compound of general formula lVb is reacted with at least one compound of general formula R 3 —H, wherein R 3  represents a —NR 7 R 8  moiety, whereby R 7  and R 8  have the meaning according to  claim 1 , in a reaction medium, in the presence of at least one coupling agent, optionally in the presence of at least one base, to yield at least one compound of general formula I, wherein R 1 , R 2 , X, R 4  and R 5  have the meaning according to  claim 1 , R 3  represents a —NR 7 R 8  moiety and R 5 is unlike hydrogen, which is optionally purified and/or isolated.  
       
     
     
         21 . Medicament comprising at least one compound according to  claim 1  including the aformenentioned excluded compounds and optionally at least one physiologically acceptable auxiliary agent.  
     
     
         22 . Medicament according to  claim 21  for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB 1 ) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.  
     
     
         23 . Medicament according to  claim 21  for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetes mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.  
     
     
         24 . Medicament according to  claim 21  for the prophylaxis and/or treatment of psychosis.  
     
     
         25 . Medicament according to  claim 21  for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction and/or nicotine abuse and/or nicotine addiction.  
     
     
         26 . Medicament according to  claim 21  for the prophylaxis and/or treatment of cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer.  
     
     
         27 . Medicament according to  claim 21  for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, sex hormone deficiency, or aging), cancer-associated bone disease or Paget's disease of bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebella disorders, spinocerebella disorders, cognitive disorders, cranial trauma, head trauma, stroke, panic attacks, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymus disorders, tardive dyskinesia, bipolar disorders, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.  
     
     
         28 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB 1 ) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.  
     
     
         29 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetes mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.  
     
     
         30 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the prophylaxis and/or treatment of psychosis.  
     
     
         31 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction and/or nicotine abuse and/or nicotine addiction.  
     
     
         32 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the prophylaxis and/or treatment of cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer.  
     
     
         33 . Use of at least one substituted pyrazoline compound according to  claim 1  for the preparation of a medicament for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, sex hormone deficiency, or aging), cancer-associated bone disease or Paget's disease of bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebella disorders, spinocerebella disorders, cognitive disorders, cranial trauma, head trauma, stroke, panic attacks, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimier, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.  
     
     
         34 . A method of modulating cannabinoid-receptors, preferably cannabinoid 1 (CB 1 ) receptors, of preventing and/or treating disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders, comprising administering to a subject, preferably a human, therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1 .  
     
     
         35 . A method of treating food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), more preferably obesity, comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1 .  
     
     
         36 . A method of treating psychosis comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1 .  
     
     
         37 . A method of treating alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction and/or nicotine abuse and/or nicotine addiction, comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1 .  
     
     
         38 . A method of treating of cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1 .  
     
     
         39 . A method of treating one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer-associated bone disease or Paget's disease of bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, head trauma, stroke, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, medicarnent-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhoea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit, comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound according to  claim 1.